NY-BOTIFY
13.12.2022 10:01:55 CET | Business Wire | Press release
Botify, the leading enterprise software company for performance-driven organic search, is closing out 2022 by appointing a series of global executive hires and company advisors. The decision comes in response to continued industry and company growth, illustrating the company’s commitment to driving innovation, delivering excellence across all areas of the business and supporting customers with every opportunity to leverage organic search as a high-impact performance marketing channel.
“I’m thrilled to welcome Brian Marin, Phil Young, Vincent Gonnot, A.J. Ghergich, and Steve Sadove to Botify as we expand how we help global brands improve how they are found in organic search,” said Botify CEO, Adrien Menard. “Each of these leaders will be extremely instrumental in supporting our continued growth and new announcements in the coming months. As we embrace widespread recognition of the impact organic search has on company performance, and define Botify’s next chapter to meet growing demand, I’m confident that together, we will do great things.”
Former Smartly.io executive Brian Marin joined in August as Senior Vice President of Global Services. In this newly created role, Marin will launch a consulting service practice and expand professional services to meet continued customer demand. A seasoned digital marketer, Marin brings decades of SaaS experience and a proven track record building and leading services functions for companies in hyper-growth mode.
Joining Marin’s growing team, Botify welcomed A.J. Ghergich as Vice President of Consulting Services to lead the rollout of Botify’s new consulting service offering. Ghergich brings more than 15 years of organic search and digital marketing experience consulting for Fortune 500 global brands.
Phil Young, Vice President of Sales of Northern Europe, joined Botify in July, focusing on leading sales teams across Northern Europe including the UK, Denmark, Finland, Sweden, and the Netherlands. Young will be working closely with the marketing and product teams to drive growth and ensure the highest success level for his teams. Young brings more than 25 years’ experience driving sales results and joins Botify from Sitecore, the leading provider of end-to-end digital experience software, where he was Area Vice President of Northern EMEA.
Focusing on European expansion, Vincent Gonnot also joined Botify as Vice President of Sales Central/South EMEA in December. Similar to Young, Gonnot will be working alongside the marketing and product teams to ensure optimal regional growth for the company. Gonnot has more than 20 years of international sales and management experience across large companies and startups.
Additionally, Steve Sadove, Principal at Stephen Sadove and Associates, has joined Botify as an advisor, helping to provide high-level counsel to inform the company’s continued growth trajectory. Throughout his career serving as CEO of several retail and consumer brands, Sadove has mastered a deep understanding of how leveraging the right technologies can transform the entire landscape for a business. He will be instrumental in helping Botify achieve amplified success as an essential solution across global organizations.
About Botify
Botify is a global, enterprise software company focused on enabling the most ambitious brands to leverage organic search as a high-impact, performance marketing channel. Powered by AI and a proprietary unified data model, Botify’s platform ensures web and mobile sites are optimized for search, the foundation of being found by consumers in today’s dynamic digital environment. As the leader in organic search innovation, Botify is trusted by more than 500 of the world’s most visible brands, including Expedia, L'Oréal, Crate & Barrel, and The New York Times, all of whom have succeeded in leveraging organic search for exponential, long-term results and revenue growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom